NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

Triptorelin的全球市場(2020年∼2027年)

Global Triptorelin Market - 2020-2027

出版商 DataM Intelligence 商品編碼 965967
出版日期 按訂單生產 內容資訊 英文
商品交期: 請詢問到貨日
價格
Triptorelin的全球市場(2020年∼2027年) Global Triptorelin Market - 2020-2027
出版日期: 按訂單生產內容資訊: 英文
簡介

全球Triptorelin市場成長,起因於各種治療適應症用Triptorelin的研究開發增加。由於民間廠商和調查機關,各種治療適應症的應用的Triptorelin的研究開發的增加,促進市場成長,為了擴大乳癌及人類免疫力缺乏病毒(HIV)的Triptorelin的潛在用途,幾個臨床試驗進行中。

本報告提供全球Triptorelin市場的相關調查,市場機會,成長及阻礙因素,COVID-19大流行的影響,各藥物類型、用途、流通管道、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 市場定義和概要

第3章 摘要整理

  • 各藥物類型的市場明細
  • 各用途的市場明細
  • 各流通管道的市場明細
  • 各地區的市場明細

第4章 市場動態

  • 影響市場的要素
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 產業分析

  • 波特的五力分析
  • 開發平台分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 COVID-19的影響分析

  • 市場上的Covid-19分析
  • Covid-19的價格動態
  • 需求與供給的頻譜
  • 大流行時的市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 市場分析:各藥物類型

  • 簡介
  • 市場規模分析,及與前一年同期比較成長分析
  • 市場魅力指數
    • Triptorelin Pamoate
    • Triptorelin Acetate
    • Triptorelin Embonate

第8章 市場分析:各用途

  • 簡介
  • 市場規模分析,及與前一年同期比較成長分析
  • 市場魅力指數
    • 前列腺癌症
    • 唾液腺癌症
    • 根治性前列腺切除術
    • 子宮內膜異位症
    • 中樞性青春期已經發病
    • 其他

第9章 市場分析:各流通管道

  • 簡介
  • 市場規模分析,及與前一年同期比較成長分析
  • 市場魅力指數
    • 零售店
    • 線上藥局
    • 醫院藥局
    • 其他

第10章 市場分析:各地區

  • 簡介
  • 市場規模分析,及與前一年同期比較成長分析
  • 市場魅力指數
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東和非洲

第11章 競爭情形

  • 競爭模式
  • 市場定位/佔有率分析
  • 合併和收購分析

第12章 企業簡介概要

  • Ipsen
    • 企業概要
    • 產品系列、概要
    • 要點
    • 財務概要
  • Debiopharm Group
  • Bachem
  • Ferring Pharmaceuticals Pvt Ltd.
  • Chengdu Tiantaishan pharmaceutical Co., Ltd.
  • Tecnofarma
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.)
  • Arbor Pharmaceuticals, LLC

第13章 重要考察

第14章 DataM

  • 附錄
  • 關於本公司、服務
  • 諮詢方式
目錄

Market Overview

The global triptorelin market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). It was first registered in France in 1986, is currently marketed in more than 80 countries and is leading market in many territories globally. In the US, triptorelin is registered as Trelstar for prostate cancer.

Triptorelin is a peptide formulation for injection which was developed mainly for the treatment of advanced metastatic prostate cancer. Also, other indications developed subsequently include the treatment of uterine fibroids (a benign tumour of muscle tissues in the uterus), endometriosis prior to surgery, and early-onset puberty and female infertility (in vitro fertilization).

Another common use of triptorelin is for hormone replacement therapy to suppress testosterone or estrogen levels in the transgender people (in conjunction with estradiol valerate for trans women or testosterone for trans men). Cyproterone and Spironolactone acetate are other drugs used by many trans people to suppress sex hormones. Triptorelin has been used as a chemical castration agent for reducing sexual urges in sex offenders.

Market Dynamics

Increasing R&D in triptorelin for various therapeutic indications is driving the market growth

Increasing research and development in triptorelin for applications in various therapeutic indications, by private manufacturers and research organizations is driving the growth of the market. Several clinical trials are undergoing to expand the potential future application of triptorelin in breast cancer and Human Immunodeficiency Virus (HIV). Also, the wide application of triptorelin in prostate cancer, salivary gland cancer, and central precious puberty are expected to fuel the growth of the market during the forecast period. Furthermore, higher efficacy and tolerability of triptorelin in the suppression of gonadotropin secretion in prostate cancer and precocious puberty is increasing adoption of triptorelin in the market.

Development of products by major manufacturers to expand their presence globally is also boosting the market growth

Pharmaceutical manufacturers of triptorelin products are updating their product portfolio by implementing inorganic growth strategies to sustain their foothold in the market. For instance, in June 2019, Debiopharm and Ipsen announced the renewal of their Decapeptyl agreement, which extends and strengthens their strategic partnership through 2034 for the development, manufacturing and distribution of Decapeptyl across Europe and certain Asian and African markets.

In October 2017, Arbor Pharmaceuticals, LLC and Debiopharm International SA made commercially available Triptodur (triptorelin), in the U.S. for the treatment of pediatric patients two years and older diagnosed with Central Precocious Puberty (CPP).

Also, in January 2016, both the companies jointly announced the execution of a distribution agreement for the commercialization and promotion of triptorelin 22.5 mg in the U.S. for central precocious puberty (CPP).

Side effects asscoated with Triptorelin are likely to hamper the market growth

Triptorelin has some side effects which might hamper the growth of the market. Some of the general side effects include anaphylaxis, arthralgia, asthenia, asthma, breast tenderness (males and females), changes in blood pressure, changes in breast size, depression, ovarian cysts, mood changes, skin rashes, hot flushes, among others.

COVID-19 Impact Analysis

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets. The global triptorelin market has slowed down from the COVID-19 pandemic, as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19.

Segment Analysis

The global Triptorelin market is segmented on the basis of drug type, application, and distribution channel.

By Drug type, Triptorelin Pamoate is expected to witness rapid growth

On the basis of drug type, the triptorelin market is segmented into triptorelin pamoate, triptorelin acetate, and triptorelin embonate. Among these, the triptorelin pamoate is expected to grow at the fastest growth rate during the forecast period. Debiopharm has developed three sustained-release formulations (one, three and six months) of triptorelin pamoate.

Triptorelin is marketed under different brand names such as Decapeptyl (Ipsen) and Diphereline and Gonapeptyl (Ferring Pharmaceuticals). In the United States, it is sold as Trelstar by Watson Pharmaceuticals and as Triptodur (an extended-release 6-month depot injection) by Arbor Pharmaceuticals. In Iran, triptorelin is marketed under the brand name Variopeptyl.

Triptodur is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of pediatric patients two years and older with central precocious puberty. Triptodur is for extended-release injectable suspension, for intramuscular use.

By application, Prostate Cancer is dominating the maximum market share

Prostate cancer is one of the most common cancers in American men, and this is made apparent by the statistics surrounding it. It is estimated by the American Cancer Society that in 2019 there will be about 174,650 men with newly diagnosed prostate cancer which is a 6% increase from 2018. There will also be an estimated 31,620 deaths from prostate cancer in 2019, a 7% increase from 2018. According to Zero Cancer, every 17 minutes, another man in the U.S. dies from prostate cancer, which is about 86 deaths per day. The number of deaths are increasing year after year, making prostate cancer the second leading cause of cancer death in men in the United States.

Triptorelin is used to treat prostate cancer (PCa) as part of androgen deprivation therapy (ADT). Another ADT injectable medicine commonly used to treat PCa includes Lupron, which also targets the pituitary. Other modalities of triptorelin such as triptorelin acetate, triptorelin pamoate and triptorelin embonate are also used for prostate cancer treatment.

Geographical Analysis

North America region holds the largest market share in the global Triptorelin market

North America region is dominating the global Triptorelin market accounted for the largest market share in 2019, owing to rising incidence of prostate cancer and salivary gland cancer and growing prevalence of central precocious puberty among the young patients below age of eight and nine years. For instance, as per the National Organization for Rare Disorders (NORD), the Central Precocious Puberty (CPP), accounting for about 1 to 5 in 10,000 children with a female to male ratio of about 20:1, in the U.S.

Europe is the second largest market in the global triptorelin market

Europe triptorelin market growth is attributable to due to growing prevalence of prostate cancer, increasing approvals of drugs for different indications in european countries. For instnace, In March 2017, Debiopharm International, a Swiss-based company, part of Debiopharm Group, announced that triptorelin 6-month formulation (Decapeptyl and Pamorelin 22.5 mg) received approval for the treatment of central precocious puberty (CPP) in 22 European countries, where the 6-month formulation has already been registered for the treatment of prostate cancer.

Also, in March 2017, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, in coordination with fourteen other European regulatory agencies approved a new indication of Decapeptyl (triptorelin). As per these new indication, Decapeptyl (triptorelin) is used as adjuvant treatment in combination with tamoxifen or aromatase inhibitor for endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy. This would enhance the revenue for growth for triptorelin market in Europe over the forecast period.

Also, in August 2016, Teva Pharmaceutical Industries Ltd. completed the acquisition of Allergan's generics business: Actavis Generics. This strategic acquisition combines two leading generic business with complementary strengths, research and development (R&D) capabilities, product pipeline and portfolio, operational expertise and also help to harness geographical footprint capabilities.

The major players in the market are engaged in expanding their product portfolio in various geographical areas. For instance, in January 2019, Debiopharm Group announced an agreement with Allergan to initiate a transition process for Trelstar (Triptorelin pamoate) intended to lead to new licensees taking over the commercialization of Trelstar in the U.S. and Canada and the termination of Allergan's partnership with Debiopharm for strategic reasons.

Competitive Landscape

The Triptorelin market is moderately competitive. The rising drug development may witness the entry of few small- or mid-sized companies in the market during the forecast period. Some of the key players which are contributing to the growth of the market include Ipsen, Debiopharm Group, Bachem , Ferring Pharmaceuticals Pvt Ltd., Chengdu Tiantaishan pharmaceutical Co., Ltd., Tecnofarma, Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.), Arbor Pharmaceuticals, LLC, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the triptorelin market globally.

Debiopharm Group

Overview:

Debiopharm Group is a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management. Debiopharm focuses on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.

Product Portfolio:

Debiopharm has developed three sustained-release formulations (1, 3 and 6 months) of triptorelin pamoate.

Decapeptyl®/Trelstar®/Pamorelin®/Triptodur®, is a GnRH agonist analogue. An agonist is a chemical that binds to a receptor of a cell and triggers a response by that cell. Triptorelin decreases the serum testosterone to castrate levels (estradiol in females).

Key Development:

  • In January 2019, Debiopharm Group announced an agreement with Allergan to initiate a transition process for Trelstar (Triptorelin pamoate) intended to lead to new licensees taking over the commercialization of Trelstar in the US and Canada and the termination of Allergan's partnership with Debiopharm for strategic reasons.

Why Purchase the Report?

  • Visualize the composition of the triptorelin market segmentation by drug type, application, and distribution channel highlighting the key commercial assets and players.
  • Identify commercial opportunities in triptorelin market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of triptorelin market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global triptorelin market report would provide an access to an approx. 58 market data table, 55 figures and 220 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Triptorelin Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Triptorelin Market - Market Definition and Overview

3. Global Triptorelin Market - Executive Summary

  • 3.1. Market Snippet by Drug Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Triptorelin Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising incidence of prostate cancer and salivary gland cancer
      • 4.1.1.2. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent regulatory approvals
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Triptorelin Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Pipeline Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Global Triptorelin Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Triptorelin Market - By Drug Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
  • 7.3. Market Attractiveness Index, By Drug Type Segment
    • 7.3.1. Triptorelin Pamoate*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Triptorelin Acetate
    • 7.3.3. Triptorelin Embonate

8. Global Triptorelin Market - By Application

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.3. Market Attractiveness Index, By Application Segment
    • 8.3.1. Prostate Cancer*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Salivary Gland Cancer
    • 8.3.3. Radical Prostatectomy
    • 8.3.4. Endometriosis
    • 8.3.5. Central Precocious Puberty
    • 8.3.6. Others

9. Global Triptorelin Market - By Distribution Channel

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 9.3. Market Attractiveness Index, By Distribution Channel Segment
    • 9.3.1. Retail Stores*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Online Pharmacy
    • 9.3.3. Hospital Pharmacy
    • 9.3.4. Others

10. Global Triptorelin Market - By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Global Triptorelin Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Triptorelin Market- Company Profiles

  • 12.1. Ipsen*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Debiopharm Group
  • 12.3. Bachem
  • 12.4. Ferring Pharmaceuticals Pvt Ltd.
  • 12.5. Chengdu Tiantaishan pharmaceutical Co., Ltd.
  • 12.6. Tecnofarma
  • 12.7. Dr. Reddy's Laboratories Ltd.
  • 12.8. Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.)
  • 12.9. Arbor Pharmaceuticals, LLC

LIST NOT EXHAUSTIVE

13. Global Triptorelin Market - Premium Insights

14. Global Triptorelin Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us